Kazuo Nishimura

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 175 citations · Full text

Platinum-based Therapy, Urology, Metastatic Urothelial Carcinoma +8

Retinoblastoma, a Tumor Suppressor, Is a Coactivator for the Androgen Receptor in Human Prostate Cancer DU145 Cells

Shuyuan Yeh, Hiroshi Miyamoto, Kazuo Nishimura et al. · Biochemical and Biophysical Research Communications · 1998 · 134 citations · Full text

Androgen Receptor, Retinoblastoma Protein, Cancer Biology +17

Increased Infiltration of Tumor Associated Macrophages is Associated With Poor Prognosis of Bladder Carcinoma In Situ After Intravesical Bacillus Calmette-Guerin Instillation

Hitoshi Takayama, Kazuo Nishimura, Akira Tsujimura et al. · The Journal of Urology · 2009 · 133 citations

Radical Cystectomy, Surgical Oncology, Pathology +19